METROSIL
2.3.2016 04:01:55 CET | Business Wire | Press release
Metrosil , the world leader in silicon carbide non-linear resistors (called varistors) today announced the launch of its new range of De-Excitation Units - the “Metrosil 8000 Series”, designed to protect large electrical generators. The all-new 8000 Series (protected by Registered Design) has been developed around an improved ergonomic structure, an industry first, providing not only protection for the varistor discs, but also simplifying the installation of the units. Another unique feature is the inclusion of a high energy test certificate with every 8000 Series unit, providing proof that the varistors perform as required. De-Excitation varistors protect electricity generating equipment (for example in hydropower and nuclear installations) from the damaging effects of powerful high energy surges.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160301006459/en/
8000 Series features include:
- Protective bar to prevent accidental disc damage
- Anti-tamper device to ensure unit integrity
- Ergonomic handles for easy carrying and installation
- Robust, easy-access connection points
- Range of standard footprints enables consistent installation
- Nameplate –permanently displays the unit’s specification details
- Each unit shipped with certification of high energy testing
- Clearly labelled with High Energy Test “Pass” badge
James O’Brien, Metrosil’s Product Group Director, commented “Metrosil constantly innovates and responds to customer feedback. With its new design, anti-tamper and ergonomic features, the 8000 Series is a more robust, long-lasting product. All Metrosil excitation products are tested to 100% of its specification – it’s part of what makes us unique in the industry, and we’re thrilled to launch another Metrosil first for the power generation industry.”
The Metrosil commercial team will be showing the 8000 Series at industry trade shows and also to individual utilities and power generation companies. To arrange a Metrosil 8000 Series visit, email requests should be sent to Ian Rowley, Metrosil’s Business Development Manager: ianrowley@mimaterials.com .
Ends
About Metrosil
Metrosil is the leading brand of high performance over-voltage protection devices for a wide range of power generation and transmission applications around the globe. It is a product of M&I Materials Limited in Manchester, UK. Since 1936, millions of Metrosil varistors have been sold throughout the world, used in flagship power projects including:
- Three Gorges Hydroelectric Dam, China
- La Grande, Canada
- Grand Coulee Dam, USA
- Itaipu, Brazil/Paraguay
About M&I Materials Limited
M&I Materials Limited is an international manufacturing company producing Specialist Materials for Industry and Science to customers located in more than sixty countries worldwide. www.mimaterials.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160301006459/en/
Contact:
M&I Materials Ltd
Ian Rowley, Metrosil Business Development
Manager
Tel: +44 (0) 161 864 5490
E-mail: ianrowley@mimaterials.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom